Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DANSAC-RCT: Fosaprepitant in advanced cancer patients not receiving chemotherapy or irradiation
2015-003070-33Phase 2Terminated
- Sponsor
- University Hospital Odense
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in nausea ((none)) and Vomiting comparing Fosaprepitant with Placebo (2 arms). Primary endpoints: Primary: Change in nausea score from baseline to 24 hours and Primary: Change in number of emetic episodes from baseline to 24 hours. Started Oct 2015; status: terminated.
02
Drugs
fosaprepitant
03
Conditions
nausea ((none))Vomiting
Beyond the preview
Go deeper on 2015-003070-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003070-33.